EUVIMEDEUVIMED entdecken
Crossref

Tracking the Current Rise of Chinese Pharmaceutical Bionanotechnology

Tim Lenoir, Patrick Herron

Journal of Biomedical Discovery and Collaboration · 14.10.2009 · 4 · 8

DOI: 10.5210/disco.v4i0.2491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomedical Discovery and Collaboration, online erschienen am 14.10.2009. Verfasst von Tim Lenoir und 1 weiteren Autor:innen. Die Arbeit wurde bisher 18-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Context and Purpose of the Study Over the last decade China has emerged as a major producer of scientific publications, currently ranking second behind the US. During that time Chinese strategic policy initiatives have placed indigenous innovation at the heart of its economy while focusing internal R&D investments and the attraction of foreign investment in nanotechnology as one of their four top areas. China’s scientific research publication and nanotechnology research publication production has reached a rank of second in the world, behind only the US. Despite these impressive gains, some scholars argue that the quality of Chinese nanotech research is inferior to US research quality due to lower overall times cited rates, suggesting that the US is still the world leader. We combine citation analysis, text mining, mapping, and data visualization to gauge the development and application of nanotechnology in China, particularly in biopharmananotechnology, and to measure the impact of Chinese policy on nanotechnology research production. Results, the main findings Our text mining-based methods provide results that counter existing claims about Chinese nanotechnology research quality. Due in large part to its strategic innovation policy, China’s output of nanotechnology publications is on pace to surpass US production in or around 2012.A closer look at Chinese nanotechnology research literature reveals a large increase in research activity in China’s biopharmananotechnology research since the implementation in January, 2006 of China’s Medium & Long Term Scientific and Technological Development Plan Guidelines for the period 2006-2020 (“MLP”).

Conclusions

Since the implementation of the MLP, China has enjoyed a great deal of success producing bionano research findings while attracting a great deal of foreign investment from pharmaceutical corporations setting up advanced drug discovery operations. Given the combination of current scientific production growth as well as economic growth, a relatively low scientific capacity, and the ability of its policy to enhance such trends, China is in some sense already the new world leader in nanotechnology. Further, the Chinese national innovation system may be the new standard by which other national S&T policies should be measured.

Zitieren

APA

Lenoir, T., & Herron, P. (2009). Tracking the Current Rise of Chinese Pharmaceutical Bionanotechnology. Journal of Biomedical Discovery and Collaboration, 4, 8. https://doi.org/10.5210/disco.v4i0.2491

Vancouver

Lenoir T, Herron P. Tracking the Current Rise of Chinese Pharmaceutical Bionanotechnology. Journal of Biomedical Discovery and Collaboration. 2009;4:8. doi:10.5210/disco.v4i0.2491

BibTeX
@article{Lenoir2009,
  author = {Lenoir, Tim and Herron, Patrick},
  title = {Tracking the Current Rise of Chinese Pharmaceutical Bionanotechnology},
  journal = {Journal of Biomedical Discovery and Collaboration},
  year = {2009},
  volume = {4},
  pages = {8},
  doi = {10.5210/disco.v4i0.2491}
}
Kostenlos starten →